One session treatment (OST) is equivalent to multi-session cognitive behavioral therapy (CBT) in children with specific phobias (ASPECT): results from a national non-inferiority randomized controlled trial.

Specific phobia children and young people cognitive behavioral therapy non-inferiority one session treatment randomized controlled trial

Journal

Journal of child psychology and psychiatry, and allied disciplines
ISSN: 1469-7610
Titre abrégé: J Child Psychol Psychiatry
Pays: England
ID NLM: 0375361

Informations de publication

Date de publication:
01 2023
Historique:
accepted: 26 04 2022
pubmed: 2 8 2022
medline: 17 12 2022
entrez: 1 8 2022
Statut: ppublish

Résumé

5%-10% children and young people (CYP) experience specific phobias that impact daily functioning. Cognitive Behaviour Therapy (CBT) is recommended but has limitations. One Session Treatment (OST), a briefer alternative incorporating CBT principles, has demonstrated efficacy. The Alleviating Specific Phobias Experienced by Children Trial (ASPECT) investigated the non-inferiority of OST compared to multi-session CBT for treating specific phobias in CYP. ASPECT was a pragmatic, multi-center, non-inferiority randomized controlled trial in 26 CAMHS sites, three voluntary agency services, and one university-based CYP well-being service. CYP aged 7-16 years with specific phobia were randomized to receive OST or CBT. Clinical non-inferiority and a nested cost-effectiveness evaluation was assessed 6-months post-randomization using the Behavioural Avoidance Task (BAT). Secondary outcome measures included the Anxiety Disorder Interview Schedule, Child Anxiety Impact Scale, Revised Children's Anxiety Depression Scale, goal-based outcome measure, and EQ-5DY and CHU-9D, collected blind at baseline and six-months. 268 CYPs were randomized to OST (n = 134) or CBT (n = 134). Mean BAT scores at 6 months were similar across groups in both intention-to-treat (ITT) and per-protocol (PP) populations (CBT: 7.1 (ITT, n = 76), 7.4 (PP, n = 57), OST: 7.4 (ITT, n = 73), 7.6 (PP, n = 56), on the standardized scale-adjusted mean difference for CBT compared to OST -0.123, 95% CI -0.449 to 0.202 (ITT), mean difference -0.204, 95% CI -0.579 to 0.171 (PP)). These findings were wholly below the standardized non-inferiority limit of 0.4, suggesting that OST is non-inferior to CBT. No between-group differences were found on secondary outcomes. OST marginally decreased mean service use costs and maintained similar mean Quality Adjusted Life Years compared to CBT. One Session Treatment has similar clinical effectiveness to CBT for specific phobias in CYP and may be a cost-saving alternative.

Sections du résumé

BACKGROUND
5%-10% children and young people (CYP) experience specific phobias that impact daily functioning. Cognitive Behaviour Therapy (CBT) is recommended but has limitations. One Session Treatment (OST), a briefer alternative incorporating CBT principles, has demonstrated efficacy. The Alleviating Specific Phobias Experienced by Children Trial (ASPECT) investigated the non-inferiority of OST compared to multi-session CBT for treating specific phobias in CYP.
METHODS
ASPECT was a pragmatic, multi-center, non-inferiority randomized controlled trial in 26 CAMHS sites, three voluntary agency services, and one university-based CYP well-being service. CYP aged 7-16 years with specific phobia were randomized to receive OST or CBT. Clinical non-inferiority and a nested cost-effectiveness evaluation was assessed 6-months post-randomization using the Behavioural Avoidance Task (BAT). Secondary outcome measures included the Anxiety Disorder Interview Schedule, Child Anxiety Impact Scale, Revised Children's Anxiety Depression Scale, goal-based outcome measure, and EQ-5DY and CHU-9D, collected blind at baseline and six-months.
RESULTS
268 CYPs were randomized to OST (n = 134) or CBT (n = 134). Mean BAT scores at 6 months were similar across groups in both intention-to-treat (ITT) and per-protocol (PP) populations (CBT: 7.1 (ITT, n = 76), 7.4 (PP, n = 57), OST: 7.4 (ITT, n = 73), 7.6 (PP, n = 56), on the standardized scale-adjusted mean difference for CBT compared to OST -0.123, 95% CI -0.449 to 0.202 (ITT), mean difference -0.204, 95% CI -0.579 to 0.171 (PP)). These findings were wholly below the standardized non-inferiority limit of 0.4, suggesting that OST is non-inferior to CBT. No between-group differences were found on secondary outcomes. OST marginally decreased mean service use costs and maintained similar mean Quality Adjusted Life Years compared to CBT.
CONCLUSIONS
One Session Treatment has similar clinical effectiveness to CBT for specific phobias in CYP and may be a cost-saving alternative.

Identifiants

pubmed: 35915056
doi: 10.1111/jcpp.13665
pmc: PMC10087411
doi:

Banques de données

ISRCTN
['ISRCTN19883421']

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-49

Informations de copyright

© 2022 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for Child and Adolescent Mental Health.

Références

Depress Anxiety. 2016 Jul;33(7):667-75
pubmed: 26990012
Can Fam Physician. 2005 Jul;51:992-3
pubmed: 16926952
Psychol Assess. 2017 Jul;29(7):835-843
pubmed: 27845527
BMJ. 1996 Jul 6;313(7048):36-9
pubmed: 8664772
J Consult Clin Psychol. 2009 Jun;77(3):504-16
pubmed: 19485591
Value Health. 2012 Dec;15(8):1092-9
pubmed: 23244812
Scand J Prim Health Care. 2011 Sep;29(3):176-80
pubmed: 21861599
J Child Adolesc Psychopharmacol. 2004 Spring;14(1):105-14
pubmed: 15142397
Behav Cogn Psychother. 2014 Jul;42(4):497-501
pubmed: 23829940
J Child Psychol Psychiatry. 1995 Mar;36(3):427-37
pubmed: 7782406
BMJ Open. 2018 Aug 17;8(8):e025031
pubmed: 30121618
Clin Psychol Rev. 2013 Jul;33(5):698-711
pubmed: 23742782
J Consult Clin Psychol. 2001 Oct;69(5):814-24
pubmed: 11680558
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Annu Rev Clin Psychol. 2019 May 7;15:233-256
pubmed: 30550722
BMC Psychiatry. 2022 Aug 12;22(1):547
pubmed: 35962334
J Clin Psychiatry. 2011 Jan;72(1):43-50
pubmed: 20816036
BMJ Open. 2014 Oct 31;4(10):e006488
pubmed: 25361841
Behav Ther. 2015 Mar;46(2):141-55
pubmed: 25645164
Behav Ther. 2018 Jul;49(4):594-603
pubmed: 29937260
Behav Res Ther. 2005 Mar;43(3):309-22
pubmed: 15680928
Soc Psychiatry Psychiatr Epidemiol. 2004 Jun;39(6):435-41
pubmed: 15205727
J Public Health Dent. 2011 Winter;71(s1):S52-S63
pubmed: 21499543
J Child Psychol Psychiatry. 2007 Dec;48(12):1174-83
pubmed: 18093022
Behav Res Ther. 2015 Sep;72:30-7
pubmed: 26164621
Clin Child Fam Psychol Rev. 2017 Jun;20(2):162-184
pubmed: 27995381
J Behav Ther Exp Psychiatry. 2017 Mar;54:128-134
pubmed: 27474792
PLoS One. 2022 Sep 15;17(9):e0274424
pubmed: 36107883
Behav Cogn Psychother. 2014 May;42(3):269-82
pubmed: 24495357
World Psychiatry. 2014 Oct;13(3):257-8
pubmed: 25273295

Auteurs

Barry Wright (B)

Leeds and York Partnership NHS Foundation Trust, York, UK.

Lucy Tindall (L)

Leeds and York Partnership NHS Foundation Trust, York, UK.

Alexander J Scott (AJ)

Keele University, Keele, UK.

Ellen Lee (E)

University of Sheffield, Sheffield, UK.

Cindy Cooper (C)

University of Sheffield, Sheffield, UK.

Katie Biggs (K)

University of Sheffield, Sheffield, UK.

Penny Bee (P)

University of Manchester, Manchester, UK.

Han-I Wang (HI)

University of York, York, UK.

Lina Gega (L)

University of York, York, UK.

Emily Hayward (E)

Leeds and York Partnership NHS Foundation Trust, York, UK.

Kiera Solaiman (K)

University of Sheffield, Sheffield, UK.

M Dawn Teare (MD)

Keele University, Keele, UK.

Thompson Davis (T)

Louisiana State University, Baton Rouge, LA, USA.

Jon Wilson (J)

Norfolk and Suffolk NHS Foundation Trust, Norwich, UK.

Karina Lovell (K)

University of Manchester, Manchester, UK.

Dean McMillan (D)

University of York, York, UK.

Amy Barr (A)

University of Sheffield, Sheffield, UK.

Hannah Edwards (H)

Leeds and York Partnership NHS Foundation Trust, York, UK.

Jennifer Lomas (J)

University of Sheffield, Sheffield, UK.

Chris Turtle (C)

University of Sheffield, Sheffield, UK.

Steve Parrott (S)

University of York, York, UK.

Catarina Teige (C)

Leeds and York Partnership NHS Foundation Trust, York, UK.

Tim Chater (T)

University of Sheffield, Sheffield, UK.

Rebecca Hargate (R)

Leeds and York Partnership NHS Foundation Trust, York, UK.

Shezhad Ali (S)

University of York, York, UK.

Sarah Parkinson (S)

Leeds and York Partnership NHS Foundation Trust, York, UK.

Simon Gilbody (S)

University of York, York, UK.

David Marshall (D)

University of York, York, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH